Back to top
more

Ayala Pharmaceuticals, Inc. (ADXS)

(Delayed Data from OTC)

$0.57 USD

0.57
2,462

0.00 (0.35%)

Updated Apr 19, 2024 01:47 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.

QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

by Zacks Equity Research

QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session

by Zacks Equity Research

Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ADXS) Outperforming Other Medical Stocks This Year?

Advaxis Up on Positive Early-Stage Immunotherapy Study Data

by Zacks Equity Research

Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.

Will Advaxis Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Advaxis.

Top Ranked Momentum Stocks to Buy for March 28th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 28th.

Top Ranked Momentum Stocks to Buy for March 27th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 27th:

Top Ranked Momentum Stocks to Buy for March 25th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 25th:

Has Advaxis (ADXS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (ADXS) Outperforming Other Medical Stocks This Year?

Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher

by Zacks Equity Research

Seres Therapeutics (MCRB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Advaxis (ADXS) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Advaxis (ADXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Advaxis (ADXS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Advaxis (ADXS) delivered earnings and revenue surprises of -107.14% and 2.64%, respectively, for the quarter ended October 2018. Do the numbers hold clues to what lies ahead for the stock?

Will Advaxis (ADXS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Advaxis (ADXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: AMGN Resubmits Evenity BLA, Advaxis Soars, Regulatory Updates

by Zacks Equity Research

It has been a pretty ho-hum week for the biotech sector with a few regulatory updates. Amgen resubmits BLA for osteoporosis drug and Advaxis surges on positive news from FDA.

    Bristol-Myers Partners Array to Investigate Cancer Candidate

    by Zacks Equity Research

    Bristol-Myers Squibb Company (BMY) and Array BioPharma (ARRY) entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's binimetinib in combination with the former's Opdivo and Opdivo + Yervoy regimen.